Document Detail

Estrogen is not neuroprotective in a rodent model of optic nerve stroke.
MedLine Citation:
PMID:  17982415     Owner:  NLM     Status:  MEDLINE    
PURPOSE: Nonarteritic anterior ischemic optic neuropathy (NAION) is an optic nerve (ON) infarct of retinal ganglion cell (RGC) axons, and the most common cause of ON-related sudden vision loss. Estrogen has been previously proposed as a neuroprotective treatment for central nervous system ischemia. We evaluated estrogen's potential in post-ON infarct treatment to reduce neuronal loss following a model of NAION, rodent anterior ischemic optic neuropathy (rAION). METHODS: We used the rat rAION model, coupled to array and northern analyses, to evaluate estrogen-associated, early post-infarct retinal gene expression changes. rAION was induced in ovariectomized female rats, which were then treated with either estrogen or vehicle. Stereological analysis of post-rAION RGC numbers was performed, using retrograde RGC fill-labeling with fluorogold. RESULTS: rAION induces an early increase in estrogen expressed transcript-1 (EET-1), but EET-1 expression is not affected by systemic estrogen pretreatment. Post-rAION, there is no significant increase in RGC numbers in estrogen treated animals compared with vehicle-treated controls. Estrogen treatment following stroke does not increase preservation of ON structure, compared with vehicle controls. CONCLUSIONS: While the rAION-axonal stroke model is a useful adjunct for evaluating potential AION neuroprotective treatments, post-stroke estrogen administration does not appear neuroprotective in this form of central nervous system insult. Similarly, estrogen is likely to be ineffective in improving ON structural integrity following an ischemic infarct.
Steven L Bernstein; Zara Mehrabyan; Yan Guo; Nima Moianie
Related Documents :
21686535 - Tennis ranking related to exercise capacity.
21618155 - Concurrent training and pulmonary function in smokers.
6800695 - The effect of some antianginal drugs on the myocardial perfusion in patients with ischa...
21222035 - Diagnostic performance of exercise bicycle testing and single-photon emission computed ...
2777935 - Nmr spectroscopic investigation of the recovery of energy and acid-base homeostasis in ...
20064545 - Leukocyte telomere length is preserved with aging in endurance exercise-trained adults ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2007-10-09
Journal Detail:
Title:  Molecular vision     Volume:  13     ISSN:  1090-0535     ISO Abbreviation:  Mol. Vis.     Publication Date:  2007  
Date Detail:
Created Date:  2007-11-05     Completed Date:  2007-12-06     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  9605351     Medline TA:  Mol Vis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1920-5     Citation Subset:  IM    
Department of Ophthalmology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Count
Estrogens / pharmacology*
Fluorescent Dyes
Infarction / etiology*,  pathology*
Neuroprotective Agents / pharmacology*
Optic Neuropathy, Ischemic / complications*
Rats, Sprague-Dawley
Retina / metabolism,  pathology
Retinal Ganglion Cells / drug effects,  pathology
Grant Support
Reg. No./Substance:
0/2-hydroxy-4,4'-diamidinostilbene, methanesulfonate salt; 0/Estrogens; 0/Fluorescent Dyes; 0/Neuroprotective Agents; 0/Stilbamidines

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Trastuzumab for early breast cancer: current status and future directions.
Next Document:  Effect of cellular senescence on the P2Y-receptor mediated calcium response in trabecular meshwork c...